NCT05918107 is a Phase 2 clinical trial of PM8002 in MPM, sponsored by Biotheus Inc..

Who is sponsoring NCT05918107?

NCT05918107 is sponsored by Biotheus Inc..

What drugs are being tested in NCT05918107?

Interventions in NCT05918107: PM8002, Pemetrexed, Cisplatin, Carboplatin.

Is NCT05918107 still recruiting?

NCT05918107 is currently recruiting now. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT05918107

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

Recruiting now Phase 2 Last updated 27 June 2023

What this trial tests

Phase 2 trial testing PM8002 in MPM in 55 participants. Currently enrolling.

Timeline

13 August 2022

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	Biotheus Inc.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	13 August 2022
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	1 location across China

Drugs / interventions tested

PM8002
Pemetrexed — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

MPM — all drugs for MPM →

Sponsor

Biotheus Inc. — full company profile →

Who can join

18 and older, any sex, with MPM. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with pemetrexed and platinum as first line treatment for MPM.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Bispecific Antibodies in Solid Tumors: Advances and Challenges.
Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, et al · · 2025 · cited 12× · PMID 40565299 · DOI 10.3390/ijms26125838
Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy.
Dong C, Wang X. · · 2026 · PMID 42145657 · DOI 10.1093/abt/tbag016
From biology to therapy: current standards and emerging strategies in pleural mesothelioma.
van Genugten JHLT, de Gooijer CJ, Baas P. · · 2026 · PMID 41971442 · DOI 10.3389/fonc.2026.1778121

Verify or expand the search:

Other trials of PM8002

Trials testing the same drug.

NCT06837948 — Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC · Phase 2 · not yet recruiting
NCT06616532 — PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer · Phase 3 · recruiting
NCT05879055 — A Study of PM8002 in Combination With Chemotherapy in Patients With NEN · Phase 2 · recruiting
NCT05918133 — A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC · Phase 1, PHASE2 · active not recruiting
NCT05879068 — A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC · Phase 2 · active not recruiting

Other Biotheus Inc. trials

Trials by the same sponsor.

NCT06616532 — PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer · Phase 3 · recruiting
NCT05537051 — A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours · Phase 1 · unknown
NCT05879055 — A Study of PM8002 in Combination With Chemotherapy in Patients With NEN · Phase 2 · recruiting
NCT05839106 — Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors · Phase 1, PHASE2 · unknown
NCT05918133 — A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05918107 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biotheus Inc.
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05918107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing